Table 1.
Baseline patient and treatment characteristics.
| Patients (N = 204) (%) | ||
|---|---|---|
| Age (y/o) | Median 69 (48~90) | |
| Age ≤ 60 | 12.7 | |
| 60 < Age ≤ 70 | 46.6 | |
| Age > 70 | 40.7 | |
| Race | White | 54.4 |
| Black | 38.7 | |
| Other | 7.8 | |
| Charlson comorbidity index | CCI = 0 | 65.2 |
| CCI = 1 | 21.1 | |
| CCI ≥ 2 | 13.7 | |
| Body mass index (BMI) | Median 27.60 (15.02–44.96) | |
| BMI ≥ 30 | 30.5 | |
| Partner status | Married or partnered | 76.0 |
| Not partnered | 24.0 | |
| Employment status | Working | 48.0 |
| Not working | 52.0 | |
| Median prostate volume (cc) | Median 39 (11.6–138.7) cc | |
| Procedure for BPH | 7.8 | |
| α1A Inhibitor usage | 27.9 | |
| Risk groups (D’Amico’s) | Low | 39.7 |
| Intermediate | 52.0 | |
| High | 8.3 | |
| ADT | 14.2 | |
| SBRT dose | 36.25 Gy | 87.7 |
| 35 Gy | 12.3 | |
| Baseline IPSS score | Median = 7.5 (0–33) | |
| Mild (0–7) | 50.0 | |
| Moderate (8–19) | 43.6 | |
| Severe (≥20) | 6.4 |